Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

被引：4

作者：

Colombo, N. ^{[1
,2
]}

Gantzer, J. ^{[3
,4
]}

Ataseven, B. ^{[5
]}

Cropet, C. ^{[6
]}

Scambia, G. ^{[7
]}

Herrero, A. ^{[8
]}

Sevelda, P. ^{[9
]}

Kobayashi, H. ^{[10
]}

Vuylsteke, P. ^{[11
]}

Mirza, M. R. ^{[12
]}

Priou, F. ^{[13
]}

Buderath, P. ^{[11
,14
]}

Pisano, C. ^{[15
]}

Lainez, N. ^{[16
]}

Guillemet, C. ^{[17
]}

Burges, A. ^{[18
]}

Sverdlin, R. ^{[19
]}

El-Balat, A. ^{[20
]}

Raban, N. ^{[21
]}

Ray-Coquard, I. L. ^{[22
,23
]}

机构：

[1] Univ Milano Bicocca, Dept Gynecol Oncol, Milan, Italy

[2] European Inst Oncol IRCCS, Milan, Italy

[3] Hop Univ Strasbourg, CCU AH Oncol Med, Strasbourg, France

[4] ICANS, Strasbourg, France

[5] Evang Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany

[6] Ctr Leon Berard, Direct Rech Clin & Innovat DRCI, Lyon, France

[7] Fdn Policlin Univ Gemelli IRCCS, Gynecol Oncol Unit, Rome, Italy

[8] Miguel Servet Univ Hosp, Med Oncol, Zaragoza, Spain

[9] Krankenhaus Hietzing Wien, Gynecol & Obstet Dept, Vienna, Austria

[10] Kagoshima Univ Hosp, Dept Obstet & Gynecol, Kagoshima, Japan

[11] CHU UCL Namur Site St Elisabeth, Dept Med Oncol, Namur, Belgium

[12] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark

[13] CHD Vendee, Hop Oudairies, Internal Med Dept Hematooncol, La Roche Sur Yon, France

[14] Univ Klinikum Essen, Dept Gynecol & Obstet, Essen, Germany

[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy

[16] Complejo Hosp Navarra, Dept Med Oncol, Pamplona, Spain

[17] Ctr Henri Becquerel, Gynecol Cancers, Rouen, France

[18] Klinikum Univ Munchen, AGO, Munich, Germany

[19] Grp Hosp St Joseph, Cancerol, Paris, France

[20] Goethe Univ, Klinikum Johann Wolfgang, Dept Gynecol & Obstet, Frankfurt, Germany

[21] CHU Poitiers, Hop Miletrie, Med Oncol Dept, Poitiers, France

[22] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[23] Univ Claude Bernard Lyon I, GINECO Grp France, Lyon, France

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.951

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

812MO

引用

页码：S614 / S614

页数：1

共 47 条

[1] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial
Grimm, C.
Cropet, C.
Ray-Coquard, I.
[J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 19 - 19
[2] RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma
Hietanen, Sakari
Pautier, Patricia
Harter, Philipp
Cropet, Claire
Cinieri, Saverio
Caballero, Cristina
Marth, Christian
Fujiwara, Hiroyuki
Vergote, Ignace
Colombo, Nicoletta
Lotz, Jean-Pierre
Gropp-Meier, Martina
Mosconi, Anna Maria
Manso, Luis
Lefeuvre-Plesse, Claudia
Luck, Hans-Joachim
Lortholary, Alain
Schnelzer, Andreas
Dubot, Coraline
Ray-Coquard, Isabelle
[J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S71 - S71
[3] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
Lorusso, Domenica
Lotz, Jean-Pierre
Harter, Philipp
Cropet, Claire
Perez, Maria Jesus Rubio
Schauer, Christian
Matsumoto, Takashi
Vergote, Ignace
Colombo, Nicoletta
Noettrup, Trine Jakobi
Bourgeois, Hugues Pierre
Schnelzer, Andreas
Pignata, Sandre
Garcia, Yolanda
Provansal, Magali
Hanker, Lars Christian
Berton, Dominique
Bauerschlag, Dirk
Joly, Florence
Ray-Coquard, Isabelle Laure
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
Gonzalez Martin, A.
Tazi, Y.
Heitz, F.
Montane, L.
Gargiulo, P.
Berger, R.
Yonemori, K.
Vergote, I.
Bologna, A.
Maenpaa, J.
Costan, C.
Canzler, U.
Zamagni, C.
Guerra-Alia, E. M.
Levache, C. B.
Marme, F.
Kalbacher, E.
De Gregorio, N.
Dohollou, N.
Ray-Coquard, I. L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1163 - S1164
[5] Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
Fujiwara, K.
Fujiwara, H.
Yoshida, H.
Satoh, T.
Yonemori, K.
Nagao, S.
Matsumoto, T.
Kobayashi, H.
Bourgeois, H.
Harter, P.
Mosconi, A. M.
Palacio, I.
Reinthaller, A.
Fujita, T.
Bloomfield, R.
Pujade-Lauraine, E.
Ray-Coquard, I. L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1335 - S1336
[6] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Ray-Coquard, I. L.
Pautier, P.
Pignata, S.
Perol, D.
Gonzalez-Martin, A.
Sevelda, P.
Fujiwara, K.
Vergote, I. B.
Colombo, N.
Maenpaa, J.
Selle, F.
Sehouli, J.
Lorusso, D.
Alia, E. M. Guerra
Lefeuvre-Plesse, C.
Canzler, U.
Lortholary, A.
Marme, F.
Pujade-Lauraine, E.
Harter, P.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 894 - +
[7] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab ( bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Schnelzer, A.
Harter, P.
Sehouli, J.
Canzler, U.
Marme, F.
De Gregorio, N.
Buderath, P.
Lueck, H. J.
Gropp-Meier, M.
Runnebaum, I
Belau, A.
Renner, S.
Schmalfeldt, B.
El-Balat, A.
Burges, A.
Hillemanns, P.
Denschlag, D.
Bauerschlag, D.
Hanker, L.
Ray-Coquard, I
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E87 - E87
[8] Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev
de Gregorio, Nikolaus
Harter, Philipp
Sehouli, Lalid
Canzler, Ulrich
Marme, Frederik
Buderath, Paul
Lueck, Hans-Joachim
Gropp-Meier, Martina
Runnebaum, Ingo B.
Belau, Antje
Renner, Stefan
Schmalfeldt, Barbara
El-Balat, Ahmed
Burges, Alexander
Hillemanns, Peter
Denschlag, Dominik
Bauerschlag, Dirk
Hanker, Lars
Schnelzer, Andreas
Ray-Coquard, Isabelle
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 93 - 93
[9] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Fujiwara, K.
Harter, P.
Leary, A.
Perol, D.
Pignata, S.
Gonzalez-Martin, A.
Petru, E.
van Nieuwenhuysen, E.
Colombo, N.
Maenpaa, J.
Selle, F.
de Gregorio, N.
Lorusso, D.
Alia, E. M. Guerra
Lefeuvre-Plesse, C.
Buderath, P.
Lortholary, A.
Burges, A.
Pujade-Lauraine, E.
Ray-Coquard, I. L.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[10] Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Gonzalez-Martin, Antonio
Desauw, Christophe
Heitz, Florian
Cropet, Claire
Gargiulo, Piera
Berger, Regina
Ochi, Hiroyuki
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor R.
Tazi, Youssef
Canzler, Ulrich
Zamagni, Claudio
Guerra-Alia, Eva M.
Levache, Charles B.
Marme, Frederik
Bazan, Fernando
de Gregorio, Nikolaus
Dohollou, Nadine
Fasching, Peter A.
Scambia, Giovanni
Rubio-Perez, Maria J.
Milenkova, Tsveta
Costan, Cristina
Pautier, Patricia
Ray-Coquard, Isabelle
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : 221 - 231

← 1 2 3 4 5 →